Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2): Compliance, Safety, and Effects on Quality of Life
Background and aims. Glucagon-like peptide 2 (GLP-2) has been shown to improve intestinal absorption in short bowel syndrome (SBS) patients in a short-term study. This study describes safety, compliance, and changes in quality of life in 11 SBS patients at baseline, week 13, 26, and 52 during two ye...
Saved in:
Main Authors: | P. B. Jeppesen, P. Lund, I. B. Gottschalck, H. B. Nielsen, J. J. Holst, J. Mortensen, S. S. Poulsen, B. Quistorff, P. B. Mortensen |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2009-01-01
|
Series: | Gastroenterology Research and Practice |
Online Access: | http://dx.doi.org/10.1155/2009/425759 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2: Effects on Intestinal Morphology and Absorption, Renal Function, Bone and Body Composition, and Muscle Function
by: P. B. Jeppesen, et al.
Published: (2009-01-01) -
Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges
by: Francisco Westermeier, et al.
Published: (2025-01-01) -
Glucagon-Like Peptide-2: New Insights-New Questions
by: Gordon R Greenberg
Published: (2001-01-01) -
A Pilot Study Examining the Relationship among Crohn Disease Activity, Glucagon-Like Peptide-2 Signalling and Intestinal Function in Pediatric Patients
by: David L Sigalet, et al.
Published: (2013-01-01) -
The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis
by: Hanieh Radkhah, et al.
Published: (2025-02-01)